In conclusion, although several small studies in lymphoma have shown that FcgR polymorphisms may be useful in predicting response to single agent rituximab [29,30,32] and have all shown the same favorable genotype, none of the analyses showed a statistically different PFS based on FcgR genotype. This evidence concerns the gene FCGR2A and lymphoma.